All In Biotech

Drug Trial Radar · NCT04117607

Safety and Pharmacokinetics of Rezafungin

A Phase 1, Three-Part, Randomized, Double-Blind, Single and Multiple Subcutaneous Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of Rezafungin in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Jul 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

14

Actual

Start

Dec 4, 2019

Primary completion

May 11, 2020

Study completion May 11, 2020

Sponsor

Sponsor type
NIH
First posted
Oct 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, double-blind, placebo-controlled trial in three parts. A single ascending dose (SAD) study in six cohorts receiving a single subcutaneous (SC) dose of 1, 10, 30, 60, 100, or 200 mg of rezafungin; a multiple ascending dose (MAD) study in four cohorts receiving 30 mg x 3 doses, 60 mg x 3 doses, 100 mg x 3 doses, or 200 mg x 3 doses of rezafungin SC with dosing frequency of once every 7 days; and a two-period cross-over bioavailability (BA) study receiving 100 mg of rezafungin. The two period cross-over BA study will be assessed unblinded in two sequences (10 subjects, 100 mg or maximum tolerated dose (MTD) of rezafungin in Part 1); 5 subjects will receive an SC injection of rezafungin in Period 1 followed by an intravenous (IV) infusion of rezafungin in Period 2, and 5 subjects will receive an IV infusion of rezafungin in Period 1 followed by an SC injection of rezafungin in Period 2. Each SAD (except cohort 1) and MAD cohort will contain 8 subjects (6 subjects will receive a SC injection of rezafungin and 2 subjects will receive placebo). Each SAD (except cohort 1) and MAD cohort will be conducted with sentinel dosing. SAD cohort 1 will be comprised of 4 subjects (3:1 rezafungin to placebo) with no sentinel dosing. Parts 2 and 3 of the study will only be conducted after FDA review for safety data and PK data from all subjects participating in Part 1; Part 3 may be run in parallel with the first cohort (Cohort 7) of Part 2. Individuals in the SAD cohorts will participate for approximately 58 days, including up to 28 days for screening and 30 days for dosing and follow-up (FU). Individuals in the MAD cohorts will participate for approximately 73 days, including up to 28 days for screening and 45 days for dosing and FU. Individuals in the BA cohorts will participate for approximately 80 days, including up to 28 days for screening and 52 days for dosing and FU. The study will have a duration of approximately 30 months. The primary objectives are to determine the: 1) safety and tolerability of single ascending SC doses (SAD) of rezafungin; 2) safety and tolerability of multiple ascending SC doses (MAD) of rezafungin; and 3) pharmacokinetic (PK) profile in plasma of rezafungin in healthy adult subjects.

Conditions

  • Fungal Infection

Interventions

  • PlaceboOther

    5% Dextrose Injection, USP, a sterile, nonpyrogenic solution of dextrose in water for injection. The solution has the osmolarity of 252 mOsmol/L, which is slightly hypotonic. This solution contains no bacteriostat, antimicrobial agent or added buffer.

  • RezafunginDrug

    Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.

  • RezafunginDrug

    Rezafungin, 200 mg/vial, is a sterile product supplied as a white to pale yellow lyophilized powder in single-dose glass vials for reconstitution with Sterile Water for Injection, United States Pharmacopeia (USP). The reconstituted product is diluted in 0.9% Sodium Chloride Injection, USP for IV infusion. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredients include excipients of mannitol, polysorbate 80, and histidine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Abnormal Chemistry Laboratory Toxicity Results for Single Ascending Dose (SAD) on Day 2Time frame: Day 2
  2. Number of Participants With Abnormal Chemistry Laboratory Toxicity Results for Single Ascending Dose (SAD) on Day 7Time frame: Day 7
  3. Number of Participants With Abnormal Chemistry Laboratory Toxicity Results for Single Ascending Dose (SAD) on Day 30Time frame: Day 30
  4. Number of Participants With Abnormal Chemistry Laboratory Toxicity Results for Multiple Ascending Dose (MAD)Time frame: Day 2 through Day 45
  5. Number of Participants With Abnormal Hematology Laboratory Toxicity Results for Single Ascending Dose (SAD) on Day 2Time frame: Day 2
  6. Number of Participants With Abnormal Hematology Laboratory Toxicity Results for Single Ascending Dose (SAD) on Day 7Time frame: Day 7
  7. Number of Participants With Abnormal Hematology Laboratory Toxicity Results for Single Ascending Dose (SAD) on Day 30Time frame: Day 30
  8. Number of Participants With Abnormal Hematology Laboratory Toxicity Results for Multiple Ascending Dose (MAD)Time frame: Day 2 through Day 45
  9. Number of Participants With Abnormal Coagulation Laboratory Toxicity Results for Single Ascending Dose (SAD), Day 2Time frame: Day 2
  10. Number of Participants With Abnormal Coagulation Laboratory Toxicity Results for Single Ascending Dose (SAD), Day 7Time frame: Day 7
  11. Number of Participants With Abnormal Coagulation Laboratory Toxicity Results for Single Ascending Dose (SAD), Day 30Time frame: Day 30
  12. Number of Participants With Abnormal Coagulation Laboratory Toxicity Results for Multiple Ascending Dose (MAD)Time frame: Day 2 through Day 45
  13. Number of Participants With Abnormal Urinalysis Laboratory Toxicity Results for Single Ascending Dose (SAD), Day 2Time frame: Day 2
  14. Number of Participants With Abnormal Urinalysis Laboratory Toxicity Results for Single Ascending Dose (SAD), Day 7Time frame: Day 7
  15. Number of Participants With Abnormal Urinalysis Laboratory Toxicity Results for Single Ascending Dose (SAD), Day 30Time frame: Day 30
  16. Number of Participants With Abnormal Urinalysis Laboratory Toxicity Results for Multiple Ascending Dose (MAD)Time frame: Day 2 through Day 45
  17. Number of Participants With Abnormal ECG Toxicity Results for Single Ascending Dose (SAD), Day 1Time frame: Day 1
  18. Number of Participants With Abnormal ECG Toxicity Results for Single Ascending Dose (SAD), Day 7Time frame: Day 7
  19. Number of Participants With Abnormal ECG Toxicity Results for Single Ascending Dose (SAD), Day 30Time frame: Day 30
  20. Number of Participants With Abnormal ECG Toxicity Results for Multiple Ascending Doses (MAD)Time frame: Day 1 through Day 45
  21. Number of Participants With Abnormal Physical Exams for Single Ascending Dose (SAD), Day 1Time frame: Day 1
  22. Number of Participants With Abnormal Physical Exams for Single Ascending Dose (SAD), Day 2Time frame: Day 2
  23. Number of Participants With Abnormal Physical Exams for Single Ascending Dose (SAD), Day 4Time frame: Day 4
  24. Number of Participants With Abnormal Physical Exams for Single Ascending Dose (SAD), Day 7Time frame: Day 7
  25. Number of Participants With Abnormal Physical Exams for Single Ascending Dose (SAD), Day 30Time frame: Day 30
  26. Number of Participants With Abnormal Physical Exams for Multiple Ascending Dose (MAD)Time frame: Day 1 through Day 45
  27. Number of Participants With Abnormal Vital Signs for Single Ascending Dose (SAD), Day 1, 15 Minutes Post-doseTime frame: Day 1, 15 minutes post-dose
  28. Number of Participants With Abnormal Vital Signs for Single Ascending Dose (SAD), Day 1, 1 Hour Post-doseTime frame: Day 1, 1 hour post-dose
  29. Number of Participants With Abnormal Vital Signs for Single Ascending Dose (SAD), Day 1, 2 Hours Post-doseTime frame: Day 1, 2 hours post-dose
  30. Number of Participants With Abnormal Vital Signs for Single Ascending Dose (SAD), Day 2Time frame: Day 2
  31. Number of Participants With Abnormal Vital Signs for Single Ascending Dose (SAD), Day 4Time frame: Day 4
  32. Number of Participants With Abnormal Vital Signs for Single Ascending Dose (SAD), Day 7Time frame: Day 7
  33. Number of Participants With Abnormal Vital Signs for Single Ascending Dose (SAD), Day 14Time frame: Day 14
  34. Number of Participants With Abnormal Vital Signs for Single Ascending Dose (SAD), Day 30Time frame: Day 30
  35. Number of Participants With Abnormal Vital Signs for Multiple Ascending Dose (MAD)Time frame: Day 1 through Day 45
  36. Number of Participants With Unsolicited Adverse Events (AEs) for Single Ascending Dose (SAD)Time frame: Day 1 through Day 30.
  37. Number of Participants With Unsolicited Adverse Events (AEs) for Multiple Ascending Dose (MAD)Time frame: Day 1 through Day 45
  38. Number of Unsolicited Adverse Events Reported for Single Ascending Dose (SAD)Time frame: Day 1 through Day 30.
  39. Number of Unsolicited Adverse Events Reported for Multiple Ascending Dose (MAD)Time frame: Day 1 through Day 45
  40. Number of Participants With at Least One Severe Adverse Event (SAE) for Single Ascending Dose (SAD)Time frame: Day 1 through Day 30
  41. Number of Participants With at Least One Severe Adverse Event (SAE) for Multiple Ascending Dose (MAD)Time frame: Day 1 through Day 45
  42. Number of Participants With Solicited Local Reactogenicity Symptom(s) for Single Ascending Dose (SAD)Time frame: Day 1 through Day 30
  43. Number of Participants With Solicited Local Reactogenicity Symptom(s) for Multiple Ascending Dose (MAD)Time frame: Day 1 through Day 45
  44. Rezafungin Concentrations in Plasma, SAD 10 mg Dose Group Concentrations of Rezafungin in Plasma SamplesTime frame: 0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 96 h, 144 h, 312 h, and 696 h post-dose
  45. Rezafungin PK Parameter (Cmax) in Plasma, SAD 10 mg Dose GroupTime frame: 0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 96 h, 144 h, 312 h, and 696 h post-dose
  46. Rezafungin PK Parameters (Tmax and t 1/2) in Plasma, SAD 10 mg Dose GroupTime frame: 0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 96 h, 144 h, 312 h, and 696 h post-dose
  47. Rezafungin PK Parameters (AUC 0-last and AUC 0-inf ) in Plasma, SAD 10 mg Dose GroupTime frame: 0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 96 h, 144 h, 312 h, and 696 h post-dose
  48. Rezafungin PK Parameter (Lambda z) in Plasma, SAD 10 mg Dose GroupTime frame: 0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 96 h, 144 h, 312 h, and 696 h post-dose
  49. Rezafungin PK Parameter (CL/F) in Plasma, SAD 10 mg Dose GroupTime frame: 0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 96 h, 144 h, 312 h, and 696 h post-dose
  50. Rezafungin PK Parameter (Vz/F) in Plasma, SAD 10 mg Dose GroupTime frame: 0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 96 h, 144 h, 312 h, and 696 h post-dose
  51. Rezafungin Concentrations in Plasma Samples, Multiple Ascending Dose (MAD)Time frame: Day 1 through Day 45
  52. Rezafungin PK Parameters in Plasma, Multiple Ascending Dose (MAD)Time frame: Day 1 through Day 45

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON Early Phase Services Clinical Research Unit

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.